Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HBM 9302

Next Previous
Drug Profile

HBM 9302

Alternative Names: Anti-HER2-anti-CD3-antibody - Glenmark; GBR-1302; HBM-9302; ISB-1302

Latest Information Update: 13 Jul 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Developer Glenmark Pharmaceuticals S.A.; Harbour BioMed
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 13 Jul 2021 Discontinued - Phase-I for Gastric cancer in USA (IV) (Glenmark Pharmaceuticals pipeline, July 2021)
  • 13 Jul 2021 Discontinued - Phase-I/II for HER2-positive-breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) (Glenmark Pharmaceuticals pipeline, July 2021)
  • 13 Jul 2021 Discontinued - Preclinical for Gastric cancer in China (IV) (Harbour Biomed pipeline, July 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top